Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Medtronic
US Department of Justice
US Army
Accenture
Johnson and Johnson
Cantor Fitzgerald
AstraZeneca
Argus Health
Cipla

Generated: August 17, 2017

DrugPatentWatch Database Preview

Vifor Fresenius Company Profile

« Back to Dashboard

What is the competitive landscape for VIFOR FRESENIUS, and what generic alternatives to VIFOR FRESENIUS drugs are available?

VIFOR FRESENIUS has one approved drug.

There are two US patents protecting VIFOR FRESENIUS drugs.

There are sixty patent family members on VIFOR FRESENIUS drugs in thirty-five countries.

Summary for Applicant: Vifor Fresenius

Patents:2
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vifor Fresenius
VELPHORO
sucroferric oxyhydroxide
TABLET, CHEWABLE;ORAL205109-001Nov 27, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Vifor Fresenius
VELPHORO
sucroferric oxyhydroxide
TABLET, CHEWABLE;ORAL205109-001Nov 27, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Vifor Fresenius
VELPHORO
sucroferric oxyhydroxide
TABLET, CHEWABLE;ORAL205109-001Nov 27, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Vifor Fresenius Drugs

Country Document Number Estimated Expiration
Germany59608089► Subscribe
Norway2015004► Subscribe
TaiwanI468167► Subscribe
Canada2240668► Subscribe
Argentina069312► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Vifor Fresenius Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
5Finland► Subscribe
00710Netherlands► SubscribePRODUCT NAME: MENGSEL VAN POLYNUCLEAIRE IJZER (III)-OXYHYDROXIDE, SUCROSE EN ZETMEEL; REGISTRATION NO/DATE: EU/1/14/943 20140826
2015 00007Denmark► SubscribePRODUCT NAME: BLANDING AF POLYNUKLEAERT JERN(III)-OXYHYDROXID, SUCROSE OG STIVELSE; REG. NO/DATE: EU/1/14/943/001-004 20140826
C0018France► SubscribePRODUCT NAME: MELANGE D'OXYHYDROXYDE DE FER (III) POLYNUCLEAIRE,DE SACCHAROSE ET D'AMIDONS.; REGISTRATION NO/DATE: EU/1/14/943/001 20140826
2015003Lithuania► SubscribePRODUCT NAME: POLICIKLINES GELEZIES (III) OKSIHIDROKSIDO, SACHAROZES IR KRAKMOLU MISINYS; REGISTRATION NO/DATE: EU/1/14/943/001 - EU/1/14/943/004 20140826
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Argus Health
Citi
Colorcon
Chinese Patent Office
Covington
Novartis
Harvard Business School
UBS
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot